Menu
Search
|

Menu

Close
X

Paratek Pharmaceuticals Inc PRTK.OQ (NASDAQ Stock Exchange Global Market)

7.35 USD
+0.17 (+2.37%)
As of 3:59 PM EST
chart
Previous Close 7.18
Open 7.18
Volume 130,063
3m Avg Volume 157,507
Today’s High 7.39
Today’s Low 7.05
52 Week High 20.90
52 Week Low 6.28
Shares Outstanding (mil) 32.14
Market Capitalization (mil) 220.17
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.55 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
13
FY16
0
FY15
0
EPS (USD)
FY18
-2.860
FY17
-3.359
FY16
-5.670
FY15
-4.228
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
42.57
22.95
Price to Book (MRQ)
vs sector
3.78
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
396.83
15.47
LT Debt to Equity (MRQ)
vs sector
396.83
11.13
Return on Investment (TTM)
vs sector
-49.97
13.00
Return on Equity (TTM)
vs sector
-141.53
14.69

EXECUTIVE LEADERSHIP

Michael Bigham
Chairman of the Board, Chief Executive Officer, Since 2014
Salary: $460,000.00
Bonus: --
Evan Loh
President, Chief Operating Officer, Chief Medical Officer, Director, Since 2017
Salary: $450,000.00
Bonus: --
Douglas Pagan
Chief Financial Officer, Since 2014
Salary: $352,000.00
Bonus: $28,336.00
William Haskel
Senior Vice President, General Counsel, Corporate Secretary, Since 2015
Salary: $348,200.00
Bonus: $28,030.00
Adam Woodrow
Vice President and Chief Commercial Officer, Since 2014
Salary: $348,200.00
Bonus: $28,030.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

75 Park Plz Ste 4
BOSTON   MA   02116-3934

Phone: +1617.8076600

Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.

SPONSORED STORIES